Part II: Testicular cancer - Management of advanced disease

Lancet Oncology

Volumn 4, Issue 12, 2003, Pages 738-747

  Jones, Robert H ^a   Vasey, Paul A ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; LACTATE DEHYDROGENASE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; GERM CELL TUMOR; HUMAN; LUNG TOXICITY; MALE; METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SEMINOMA; STEM CELL TRANSPLANTATION; TESTIS CANCER;

EID: 0347503602     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01279-8     Document Type: Review

References (78)

1. Samuels ML, Lanzotti VJ, Holoye PY, et al. Combination chemotherapy in germinal cell tumors. Cancer Treat Rev 1976; 3: 185-204.
2. Einhorn LH, Williams SD, Troner M, et al. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981; 305: 727-31.
3. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40.
4. IGCCCG. International Germ Cell Consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-601.
5. Donohue JP, Thornhill JA, Foster RS, et al. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 1995; 31A: 1599-1604.
6. Bosl GJ, Geller N, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43: 3403-09.
7. Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4: 400-07.
8. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995; 71: 1311-18.
9. Mazumdar M, Bajorin DF, Bacik J et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534-41.
10. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7: 387-91.
11. Saxinan SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 1998; 16: 702-06.
12. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and ofa 3 or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629-40.
13. Simpson AB, Paul J, Graham J, Kaye S. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998; 78: 1061-66.
14. O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14: 91-96.
15. McKeage M, Evans B, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. J Clin Oncol 1990; 8: 779-87.
16. Loehrer PJ, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors; an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13: 470-76.
17. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15: 1837-43.
18. Culine S, Kerbrat P, Bouzyet L, et al. Are 3 cycles of bleomycin, etoposide, and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent regimens for patients (pts) with good-risk metastatic non seminomatous germ cell tumors (NSGCT)? Proc Am Soc Clin Oncol 1999; 18: (abstr 1188).
19. Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell turnours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 2001; 357: 739-45.
20. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11: 598-606.
21. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15: 1844-52.
22. Nichols CR, Catalano P, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors; an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 1998; 16: 1287-93.
23. de Wit R, Louwerens M, de Mulder PH, et al. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 1999; 83: 831-33.
24. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-70.
25. Kaye S, Mead G, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701.
26. Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998; 16: 716-24.
27. Christian JA, Huddart RA, Norman A. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003; 21: 871-77.
28. Bower M, Brock C, Holden L, et al. POMB/ACE chemotherapy for mediastinal germ cell tumours. Eur J Cancer 1997; 33: 838-42.
29. Bower M, Newlands ES, Holden L, et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997; 8: 477-83.
30. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500-04.
31. McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 1997; 15: 2559-63.
32. Harstrick A, Schmoll HJ, Wilke H, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 1991; 9: 1549-57.
33. Ghosn M, Droz JP, Theodore C, et al. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP- 16) plus ifosfamide plus high-dose cisplatin. Cancer 1988; 62: 24-31.
34. Pizzocaro G, Salvoni R, Piva L. High activity, moderate toxicity modified cisplatin, etoposide, ifosfamide (PEI) salvage therapy for germ-cell testicular tumors (GCTT). Proc Am Soc Clin Oncol 1990; 9: 131a.
35. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1997; 7: 31-34.
36. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-83.
37. Motzer RJ, Sheinfeld J, Mazumdar M. Paclitaxel, ifosfomide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000; 18: 2413-18.
38. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 1996; 14: 2638-45.
39. Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19: 81-88.
40. Bhatia S, Abonour R, Porcu P, et al: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2001; 18: 3346-51.
41. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-80.
42. Doroshow JH, Margolin KA, Chow W, et al. High-dose chemotherapy with autologous stem cell rescue (PSCT) for relapsed nonseminomatous germ cell cancer (NSGCT): effective salvage for poor-risk patients (pts) in first relapse. Proc Am Soc Clin Oncol 2002; 21: (abstr 714).
43. Broun ER, Nichols CR, Turns M, et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994; 73: 1716-20.
44. Siegert W, Beyer J, Strohscheer I, et. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study - The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12: 1223-31.
45. Rosti G, Pico J, Wandt H, et al High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc Am Soc Clin Oncol 2002; 21: 716A.
46. Nichols CR, Williams S. Dose intensive chemotherapy in refractory germ cell cancer: a phase I/II trail of carboplatin and etoposide with autologous bone marrow transplant. J Clin Oncol 1987; 14: 2625-26.
47. Einhorn LH. Salvage therapy for germ cell tumors. Semin Oncol 1994; 21 (suppl 7): 47-51.
48. Motzer RJ, Mazudar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-34.
49. Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546-53.
50. Bokemeyer C, Kollmannsberger C, Meisner C, et al: First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-56.
51. Chevreau C, Droz J, Pico J, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Eur Urol 1993; 23: 213-18.
52. Dunn TA, Schmoll HJ, Grünwald V, et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines. Invest New Drugs 1997; 15: 109-14.
53. Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the german testicular cancer study group. J Clin Oncol 2002; 20: 2031-37.
54. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. 1999; 17: 509-11.
55. Bokemeyer C, Gerl A, Schoffski P, et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999: 17: 512-16.
56. Hinton S, Catalano P, Einhorn LH, et al. Phase II Study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002; 20: 1859-63.
57. Bokemeyer C, Beyer J, Metzner B, Schoeffski P. Combination chemotherapy with gemcitabine/oxaliplatin in patients (pts) with relapsed or cisplatin-refractory germ-cell cancer (GCT) Proc Am Soc Clin Oncol 2003; 22: (abstr 1561).
58. Kollmannsberger C, Rick O, Klaproth H, et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer 2002, 87: 729-32.
59. Miki T, Mizutani Y, Nonomura N, et al. Irinotecan plus cisplatin has substantial antitumor effect as a salvage chemotherapy against germ cell tumors. Cancer 2002; 95: 1879-85.
60. Fossa SD, Qvist H, Stenwig AE, et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992; 10: 569-75.
61. Fox EP, Weathers T, Williams S, et al. Outcome analysis for patients with persistent germ cell nonteratomatous germ cell tumor in post-chemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993; 11: 1294-99.
62. Toner GC, Panicek D, Heelan R, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990; 8: 1683-89.
63. Fizazi K. Tjulandin S. Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001; 19: 2647-57.
64. Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995; 153: 976-80.
65. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol 2002; 20: 262-71.
66. Krege S, Souchon R, Schmoll HJ. The German Testicular Cancer Study Group. interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 2001; 40: 372-91.
67. Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy or metastatic seminoma - a diminishing role. Eur J Can 1997; 33: 829-35.
68. Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol 1992; 19: 148-58.
69. Puc H, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996; 14: 454-60.
70. De Santis M, Bokemeyer C, Becherer A, et al Predictive impact of 2-18Fluoro-2-Deoxy-D-Glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740-48.
71. De Santis M, Becherer C, Bokemeyer F, et al. FDG-PET as prognostic indicator for seminoma residuals: an update from the multicenter SEMPET Proc Am Soc Clin Oncol 2003; 22: (abstr 1535).
72. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993; 11: 324-29.
73. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol 2002; 20: 262-71.
74. Mosheni HF, Rabanni F, Leon A, et al. Management and clinical outcome of patients with germ cell tumour and a post-chemotherapy neck mass. J Urol 2002; 167: 693A.
75. Soule SE, Porter SJ, Kesler KA, et al. Outcome of testicular non-seminomatous germ cell tumour (GCT) in patients with post-chemotherapy resection of pulmonary metastases. Proc Am Soc Clin Oncol 2002; 21: (abstr 714).
76. Madani A, Kemmer K, Sweeny C, et al. Expression of Kit and epidermal growth factor receptor (EGFR) in chemotherapy refractory non-seminomatous germ cell tumors. Proc Am Soc Clin Oncol 2002; 21: (abstr 738).
77. Kollmannsberger C, Mayer F, Pressler H, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 2002; 95: 301-08.
78. Mayer F, Stoop H, Schefer G, et al. Molecular determinants of treatment response in human germ cell tumours. Clin Cancer Res 2003; 9: 767-73.